Literature DB >> 20495204

High cumulative incidence of cancer in patients with cardio-renal-anaemia syndrome.

Nicolas F Schroten1, Karien van der Putten, Frans H Rutten, Adry Diepenbroek, Arend Mosterd, Carlo A J M Gaillard.   

Abstract

AIMS: The combination of chronic kidney disease (CKD), chronic heart failure (HF), and anaemia, the so-called cardio-renal-anaemia syndrome (CRA) is associated with dysregulation of erythropoietin levels and inflammation. Both have been associated with the development of cancer. This study aimed to determine the cumulative incidence of cancer in patients with CRA, as compared with anaemic CKD and control patients. METHODS AND
RESULTS: Patients aged <80 years who attended the nephrology or cardiology outpatient clinics between March 2006 and November 2007 were eligible for inclusion in this retrospective case-control study if haemoglobin <8.1 mmol/L (13 g/dL) and serum creatinine >80 mmol/L (0.90 mg/dL). Medical records dating back to 1996 were reviewed. The relationship between cancer and CRA, chronic HF, CKD, and anaemia was analysed using logistic regression analysis. Data from 1087 patients were reviewed. We identified 348 patients with both CKD and anaemia, of whom 132(38.3%) had CRA. The control group included 264 patients attending the hypertension outpatient clinic. Patients with CRA had a 19% cumulative incidence of cancer compared with 11% for patients with anaemia, CKD and no chronic HF, and 11% in the control group. The odds ratio (OR) for cancer was 1.8(95% CI 1.0-3.2) for the CRA group compared with the control group. Chronic HF was an independent risk factor for cancer after correction for age and gender (adjusted OR 2.0; 95% CI 1.2-3.3, P = 0.007).
CONCLUSION: The cumulative incidence of cancer among patients with CRA is high compared with controls and to anaemic CKD patients without chronic HF. Chronic HF was an independent risk factor for cancer. These results stress the importance of clarifying the mechanisms involved in the development of cancer in CRA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495204     DOI: 10.1093/eurjhf/hfq078

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  5 in total

Review 1.  Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.

Authors:  Dirk J van Veldhuisen; Stefan D Anker; Piotr Ponikowski; Iain C Macdougall
Journal:  Nat Rev Cardiol       Date:  2011-05-31       Impact factor: 32.419

2.  Patients with heart failure have an increased risk of incident cancer.

Authors:  Tal Hasin; Yariv Gerber; Sheila M McNallan; Susan A Weston; Sudhir S Kushwaha; Timothy J Nelson; James R Cerhan; Veronique L Roger
Journal:  J Am Coll Cardiol       Date:  2013-06-27       Impact factor: 24.094

3.  Influence of renal insufficiency pre-heart transplantation on malignancy risk post-heart transplantation.

Authors:  Stefan Roest; Christianne Struijk; Alina A Constantinescu; Kadir Caliskan; Elsemieke I Plasmeijer; Eric Boersma; Jasper J Brugts; Olivier C Manintveld
Journal:  ESC Heart Fail       Date:  2021-03-28

Review 4.  Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency.

Authors:  Iain C Macdougall; Bernard Canaud; Angel L M de Francisco; Gerasimos Filippatos; Piotr Ponikowski; Donald Silverberg; Dirk J van Veldhuisen; Stefan D Anker
Journal:  Eur J Heart Fail       Date:  2012-04-20       Impact factor: 15.534

5.  Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study.

Authors:  Ridha I S Alnuwaysir; Niels Grote Beverborg; Martijn F Hoes; George Markousis-Mavrogenis; Karla A Gomez; Haye H van der Wal; John G F Cleland; Kenneth Dickstein; Chim C Lang; Leong L Ng; Piotr Ponikowski; Stefan D Anker; Dirk J van Veldhuisen; Adriaan A Voors; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2021-12-09       Impact factor: 17.349

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.